Farzin Ferdousi - Department of Genetic,Biology Research Center,Zanjan Branch,Islamic Azad University,Zanjan,Iran
Amir Hossein Taromchi - Department of Biotechnology and Nanotechnology, Zanjan University of Medical Sciences, Zanjan, Iran
Abdolreza Esmaeilzadeh - Department of Immonology, Zanjan University of Medical Sciences, Zanjan, Iran

Backgrounds and Objectives: lots of genes are associated with the risk of developing diabetes. Overweight and obesity are common risk factors for type 2 diabetes (T2D) and most of the time body composition controlled by genetic factors. There are plenty of evidence to suggest that inflammatory reactions have a significant role in the incidence of these complications. Interleukin 10 is known as one of the most important anti-inflammatory cytokines. Thus, the present study was conducted to investigate the relationship between Interleukin 10 gene polymorphisms -592 A/C and -1082 A/G and susceptibility to get T2D and obesity.Materials and Methods: In this study, 75 obese patients with T2D, 75 non-obese patients with T2D, 75 obese patients without T2D and 75 healthy controls were studied. DNA extraction was carried out and then the genotype in -592 A/C and -1082A/G positions was determined using PCR-RFLP and chi squared test ( X2 ) was used as statistical methods for data analysis.Results: The frequency of CC and AC genotype in -592A/C position in obese patients with T2D and non-obese patients with T2D had more importance than non-diabetic patients (p<0.05). Also the frequency of AA genotype in -1082A/G position in obese patients with T2D was significantly more than other subjects (p<0.05) .Conclusion: Higher frequency of C allele in -592A/C position can be considered as a factor for T2D. Also the presence of an A allele next to C allele at the position of -592A/C could be predisposing of obesity in patients with T2D. Fewer frequency of haplotype AA/AA can be considered as a predisposing factor for obesity and T2D. Understanding the basis of this heterogeneity provides an opportunity for personalizing prevention and treatment strategies according to individual patient clinical and molecular characteristics.

Type 2 diabetes, obesity, polymorphism, Interleukin 10